277 related articles for article (PubMed ID: 26977885)
1. Protein Kinase Cι Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung Adenocarcinoma.
Ali SA; Justilien V; Jamieson L; Murray NR; Fields AP
Cancer Cell; 2016 Mar; 29(3):367-378. PubMed ID: 26977885
[TBL] [Abstract][Full Text] [Related]
2. Protein Kinase Cι and Wnt/β-Catenin Signaling: Alternative Pathways to Kras/Trp53-Driven Lung Adenocarcinoma.
Yin N; Liu Y; Khoor A; Wang X; Thompson EA; Leitges M; Justilien V; Weems C; Murray NR; Fields AP
Cancer Cell; 2019 Aug; 36(2):156-167.e7. PubMed ID: 31378680
[TBL] [Abstract][Full Text] [Related]
3. Targeting oncogenic protein kinase Cι for treatment of mutant KRAS LADC.
Fields AP; Ali SA; Justilien V; Murray NR
Small GTPases; 2017 Jan; 8(1):58-64. PubMed ID: 27245608
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of oncogenic protein kinase Ciota signaling in lung adenocarcinoma.
Erdogan E; Klee EW; Thompson EA; Fields AP
Clin Cancer Res; 2009 Mar; 15(5):1527-33. PubMed ID: 19223491
[TBL] [Abstract][Full Text] [Related]
5. Identification of tumorigenic cells in Kras(G12D)-induced lung adenocarcinoma.
Cho HC; Lai CY; Shao LE; Yu J
Cancer Res; 2011 Dec; 71(23):7250-8. PubMed ID: 22088965
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic protein kinase Cι signaling mechanisms in lung cancer: Implications for improved therapeutic strategies.
Yin N; Liu Y; Murray NR; Fields AP
Adv Biol Regul; 2020 Jan; 75():100656. PubMed ID: 31623973
[TBL] [Abstract][Full Text] [Related]
7. Protein kinase C
Fields AP; Ali SA; Justilien V; Murray NR
Mol Cell Oncol; 2018; 5(5):e1190886. PubMed ID: 30263934
[TBL] [Abstract][Full Text] [Related]
8. Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma.
Ito M; Codony-Servat C; Codony-Servat J; Lligé D; Chaib I; Sun X; Miao J; Sun R; Cai X; Verlicchi A; Okada M; Molina-Vila MA; Karachaliou N; Cao P; Rosell R
Cell Commun Signal; 2019 Oct; 17(1):137. PubMed ID: 31660987
[TBL] [Abstract][Full Text] [Related]
9. Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.
Ambrogio C; Gómez-López G; Falcone M; Vidal A; Nadal E; Crosetto N; Blasco RB; Fernández-Marcos PJ; Sánchez-Céspedes M; Ren X; Wang Z; Ding K; Hidalgo M; Serrano M; Villanueva A; Santamaría D; Barbacid M
Nat Med; 2016 Mar; 22(3):270-7. PubMed ID: 26855149
[TBL] [Abstract][Full Text] [Related]
10. Atypical protein kinase C{iota} is required for bronchioalveolar stem cell expansion and lung tumorigenesis.
Regala RP; Davis RK; Kunz A; Khoor A; Leitges M; Fields AP
Cancer Res; 2009 Oct; 69(19):7603-11. PubMed ID: 19738040
[TBL] [Abstract][Full Text] [Related]
11. Ect2-Dependent rRNA Synthesis Is Required for KRAS-TRP53-Driven Lung Adenocarcinoma.
Justilien V; Ali SA; Jamieson L; Yin N; Cox AD; Der CJ; Murray NR; Fields AP
Cancer Cell; 2017 Feb; 31(2):256-269. PubMed ID: 28110998
[TBL] [Abstract][Full Text] [Related]
12. PKCι maintains a tumor-initiating cell phenotype that is required for ovarian tumorigenesis.
Wang Y; Hill KS; Fields AP
Mol Cancer Res; 2013 Dec; 11(12):1624-35. PubMed ID: 24174471
[TBL] [Abstract][Full Text] [Related]
13. The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma.
Justilien V; Walsh MP; Ali SA; Thompson EA; Murray NR; Fields AP
Cancer Cell; 2014 Feb; 25(2):139-51. PubMed ID: 24525231
[TBL] [Abstract][Full Text] [Related]
14. Mu-KRAS attenuates Hippo signaling pathway through PKCι to sustain the growth of pancreatic cancer.
Wang P; Zhang H; Yang J; Li Z; Wang Y; Leng X; Ganapathy S; Isakson P; Chen C; Zhu T
J Cell Physiol; 2020 Jan; 235(1):408-420. PubMed ID: 31230347
[TBL] [Abstract][Full Text] [Related]
15. Protein kinase Ciota is required for pancreatic cancer cell transformed growth and tumorigenesis.
Scotti ML; Bamlet WR; Smyrk TC; Fields AP; Murray NR
Cancer Res; 2010 Mar; 70(5):2064-74. PubMed ID: 20179210
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of Notch Signaling in Kras-Induced Gastric Metaplasia.
Chung WC; Zhou Y; Atfi A; Xu K
Neoplasia; 2019 Aug; 21(8):810-821. PubMed ID: 31276933
[TBL] [Abstract][Full Text] [Related]
17. Survivin knockdown induces senescence in TTF‑1-expressing, KRAS-mutant lung adenocarcinomas.
Sumi T; Hirai S; Yamaguchi M; Tanaka Y; Tada M; Yamada G; Hasegawa T; Miyagi Y; Niki T; Watanabe A; Takahashi H; Sakuma Y
Int J Oncol; 2018 Jul; 53(1):33-46. PubMed ID: 29658609
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas.
Bouillez A; Rajabi H; Pitroda S; Jin C; Alam M; Kharbanda A; Tagde A; Wong KK; Kufe D
Cancer Res; 2016 Mar; 76(6):1538-48. PubMed ID: 26833129
[TBL] [Abstract][Full Text] [Related]
19. Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets.
Drosten M; Barbacid M
J Mol Med (Berl); 2016 Feb; 94(2):121-35. PubMed ID: 26526121
[TBL] [Abstract][Full Text] [Related]
20. Insulin receptor substrate-1 deficiency drives a proinflammatory phenotype in KRAS mutant lung adenocarcinoma.
Metz HE; Kargl J; Busch SE; Kim KH; Kurland BF; Abberbock SR; Randolph-Habecker J; Knoblaugh SE; Kolls JK; White MF; Houghton AM
Proc Natl Acad Sci U S A; 2016 Aug; 113(31):8795-800. PubMed ID: 27439864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
